Revisiting the role of surgery in the treatment of Graves’ disease

Graves’ disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence‐based approach to the clinicians’ preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up‐to‐date data.

[1]  J. M. Francos Martínez,et al.  Transoral endoscopic thyroidectomy vestibular approach (TOETVA). , 2021, Cirugia espanola.

[2]  G. Dionigi,et al.  Trans-oral endoscopic thyroidectomy vestibular approach (TOETVA) for the pediatric population: a multicenter, large case series , 2021, Surgical Endoscopy.

[3]  G. Wallin,et al.  Treatment of patients with Graves’ disease in Sweden compared to international surveys of an ‘index patient’ , 2021, Endocrinology, diabetes & metabolism.

[4]  R. Rajatanavin,et al.  Practice patterns and outcomes in the management of Thai patients with Graves’ disease , 2021, Thyroid Research.

[5]  R. Peeters,et al.  Patients' and clinicians' preferences for treatment for Graves' disease: A discrete choice experiment. , 2021, European journal of endocrinology.

[6]  R. Tufano,et al.  Preferences for thyroidectomy technique: Comparing traditional and transoral approaches , 2021, Head & neck.

[7]  P. V. Pradeep.  Scar satisfaction assessment after conventional thyroidectomy: follow-up results , 2021, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[8]  O. Ronen,et al.  National differences in cost analysis of Afirma Genomic sequencing classifier , 2020, Clinical endocrinology.

[9]  D. Ross,et al.  Comparison of long‐term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: A review of the literature , 2020, Clinical endocrinology.

[10]  H. Buhr,et al.  Short-Term Outcomes of Surgery for Graves’ Disease in Germany , 2020, Journal of clinical medicine.

[11]  O. Ronen,et al.  The natural neck crease as an anatomic landmark for thyroid surgery incision. , 2020, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[12]  P. Taylor,et al.  Should radioiodine now be first line treatment for Graves’ disease? , 2020, Thyroid Research.

[13]  T. Fahey,et al.  The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. , 2020, Annals of surgery.

[14]  V. Montori,et al.  Patterns of use, efficacy and safety of treatment options for patients with Graves' disease: A Nationwide Population-Based Study. , 2020, Thyroid : official journal of the American Thyroid Association.

[15]  A. Lim,et al.  Total thyroidectomy for Graves' disease-what do our patients think? A qualitative cohort study to evaluate the surgical management of Graves' disease. , 2020, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[16]  David F. Schneider,et al.  Assessing American Thyroid Association Guidelines for Total Thyroidectomy in Graves' Disease. , 2020, The Journal of surgical research.

[17]  J. Hardouin,et al.  Impact of total thyroidectomy on quality of life at 6 months: the prospective ThyrQoL multicentre trial. , 2019, European journal of endocrinology.

[18]  G. Wallin,et al.  The long-term outcome of treatment for Graves' hyperthyroidism. , 2019, Thyroid : official journal of the American Thyroid Association.

[19]  S. Yount,et al.  Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors. , 2019, Surgery.

[20]  Q. Duh,et al.  Patient Eligibility for Transoral Endocrine Surgery Procedures in the United States , 2019, JAMA network open.

[21]  G. Wallin,et al.  Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey. , 2019, Thyroid : official journal of the American Thyroid Association.

[22]  L. Rejnmark,et al.  Huge variations in definition and reported incidence of postsurgical hypoparathyroidism: a systematic review , 2019, Endocrine.

[23]  S. Vieni,et al.  The value of total thyroidectomy as the definitive treatment for Graves’ disease: A single centre experience of 594 cases , 2019, Journal of clinical & translational endocrinology.

[24]  C. Benbassat,et al.  A 2017 SURVEY OF THE CLINICAL PRACTICE PATTERNS IN THE MANAGEMENT OF RELAPSING GRAVES DISEASE. , 2019, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[25]  H. Kwon,et al.  Increased risk of postoperative complications after total thyroidectomy with Graves' disease , 2018, Head & neck.

[26]  J. Sosa,et al.  Surgical Hypoparathyroidism. , 2018, Endocrinology and metabolism clinics of North America.

[27]  S. Pearce,et al.  2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism , 2018, European Thyroid Journal.

[28]  G. Dionigi,et al.  Transoral Thyroid and Parathyroid Surgery Vestibular Approach: A Framework for Assessment and Safe Exploration. , 2018, Thyroid : official journal of the American Thyroid Association.

[29]  S. Wiseman,et al.  American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults. , 2018, Thyroid : official journal of the American Thyroid Association.

[30]  Фадеев Валентин Викторович,et al.  Review of American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. , 2017 .

[31]  Steven S. Chang,et al.  Referral Trends for Surgical Management of Graves' Disease. , 2017, Thyroid : official journal of the American Thyroid Association.

[32]  S. Johnson-Obaseki,et al.  Is there a group of patients at greater risk for hematoma following thyroidectomy? A systematic review and meta‐analysis , 2017, The Laryngoscope.

[33]  M. Benbarka,et al.  A SURVEY OF CLINICAL PRACTICE PATTERNS IN MANAGEMENT OF GRAVES DISEASE IN THE MIDDLE EAST AND NORTH AFRICA. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[34]  L. Gordon,et al.  Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves' disease. , 2016, European journal of endocrinology.

[35]  Pornpeera Jitpratoom,et al.  Transoral endoscopic thyroidectomy vestibular approach (TOETVA) for Graves' disease: a comparison of surgical results with open thyroidectomy. , 2016, Gland surgery.

[36]  N. Hope,et al.  Pre-Operative Lugol's Iodine Treatment in the Management of Patients Undergoing Thyroidectomy for Graves' Disease: A Review of the Literature , 2016, European Thyroid Journal.

[37]  S. Rivkees,et al.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. , 2016, Thyroid : official journal of the American Thyroid Association.

[38]  C. Pedone,et al.  PTH(1-34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial. , 2016, The Journal of clinical endocrinology and metabolism.

[39]  M. Thaha,et al.  Change in Practice over Four Decades in the Management of Graves' Disease in Scotland , 2016, Journal of thyroid research.

[40]  Y. J. Chai,et al.  Comparison of Bilateral Axillo-Breast Approach Robotic Thyroidectomy with Open Thyroidectomy for Graves’ Disease , 2016, World Journal of Surgery.

[41]  L. Bartalena,et al.  A 2013 European survey of clinical practice patterns in the management of Graves' disease , 2016, Clinical endocrinology.

[42]  E. Kandil,et al.  Association of Surgeon Volume With Outcomes and Cost Savings Following Thyroidectomy: A National Forecast. , 2016, JAMA otolaryngology-- head & neck surgery.

[43]  Terry J. Smith,et al.  Graves' Disease. , 2016, The New England journal of medicine.

[44]  D. Cooper,et al.  Management of Graves Disease: A Review. , 2015, JAMA.

[45]  L. Masterson,et al.  Thyroid surgery for Graves' disease and Graves' ophthalmopathy. , 2015, The Cochrane database of systematic reviews.

[46]  A. Karanikolić,et al.  Total thyroidectomy as a method of choice in the treatment of Graves’ disease - analysis of 1432 patients , 2015, BMC Surgery.

[47]  Hang-Seok Chang,et al.  Impact of Postthyroidectomy Scar on the Quality of Life of Thyroid Cancer Patients , 2014, Annals of dermatology.

[48]  J. Tamatea,et al.  Thyroid cancer in Graves’ disease: is surgery the best treatment for Graves’ disease? , 2014, ANZ journal of surgery.

[49]  O. Edafe,et al.  Systematic review and meta‐analysis of predictors of post‐thyroidectomy hypocalcaemia , 2014, The British journal of surgery.

[50]  GanlyIan,et al.  American Thyroid Association Statement on Optimal Surgical Management of Goiter , 2014 .

[51]  Y. Tomer.  Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. , 2014, Annual review of pathology.

[52]  H. Lippert,et al.  Multivariate Analysis of Risk Factors for Postoperative Complications in Benign Goiter Surgery: Prospective Multicenter Study in Germany , 2000, World Journal of Surgery.

[53]  H. Röher,et al.  Surgery for Graves' Disease: Total versus Subtotal Thyroidectomy—Results of a Prospective Randomized Trial , 2000, World Journal of Surgery.

[54]  David F. Schneider,et al.  Preventing Postoperative Hypocalcemia in Patients with Graves Disease: A Prospective Study , 2014, Annals of Surgical Oncology.

[55]  Amy Y. Chen,et al.  American Thyroid Association statement on optimal surgical management of goiter. , 2014, Thyroid : official journal of the American Thyroid Association.

[56]  L. Bartalena.  Diagnosis and management of Graves disease: a global overview , 2013, Nature Reviews Endocrinology.

[57]  C. Solórzano,et al.  Total thyroidectomy for Graves' disease: compliance with American Thyroid Association guidelines may not always be necessary. , 2013, Surgery.

[58]  Jesse M. Ehrenfeld,et al.  Surgery for Graves' disease: a 25-year perspective. , 2013, American journal of surgery.

[59]  C. Solórzano,et al.  Is Potassium Iodide Solution Necessary Before Total Thyroidectomy for Graves Disease? , 2013, Annals of Surgical Oncology.

[60]  A. Petralias,et al.  Patient Attitudes toward Transaxillary Robot-assisted Thyroidectomy , 2013, World Journal of Surgery.

[61]  S. Jansson,et al.  Incidence rate and clinical features of hyperthyroidism in a long‐term iodine sufficient area of Sweden (Gothenburg) 2003–2005 , 2013, Clinical endocrinology.

[62]  E. Amodio,et al.  Does thyroid surgery for Graves’ disease improve health-related quality of life? , 2013, Surgery Today.

[63]  E. Kandil,et al.  What Is the Best Definitive Treatment for Graves’ Disease? A Systematic Review of the Existing Literature , 2013, Annals of Surgical Oncology.

[64]  K. Burman,et al.  A 2011 survey of clinical practice patterns in the management of Graves' disease. , 2012, The Journal of clinical endocrinology and metabolism.

[65]  A. Sehgal,et al.  Disparity in the management of Graves' disease observed at an urban county hospital: a decade-long experience. , 2012, American journal of surgery.

[66]  C. Sturgeon,et al.  Is subtotal thyroidectomy a cost-effective treatment for Graves disease? A cost-effectiveness analysis of the medical and surgical treatment options. , 2012, Surgery.

[67]  P. Doyle,et al.  The Western Surgical Concern Inventory–Thyroid , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[68]  B. Lang,et al.  Changing trend in surgical indication and management for Graves' disease. , 2012, American journal of surgery.

[69]  C. McHenry,et al.  Total thyroidectomy: is morbidity higher for Graves' disease than nontoxic goiter? , 2011, The Journal of surgical research.

[70]  L. Hegedüs,et al.  The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. , 2011, Thyroid : official journal of the American Thyroid Association.

[71]  R. Sataloff,et al.  Recurrent laryngeal nerve monitoring versus identification alone on post‐thyroidectomy true vocal fold palsy: A meta‐analysis , 2011, The Laryngoscope.

[72]  D. Pothier,et al.  Scars and satisfaction: do smaller scars improve patient-reported outcome? , 2011, European Archives of Oto-Rhino-Laryngology.

[73]  A. Dackiw,et al.  Postoperative hypocalcemia after thyroidectomy for Graves' disease. , 2010, Thyroid : official journal of the American Thyroid Association.

[74]  C. McHenry,et al.  Total Thyroidectomy Is Superior to Subtotal Thyroidectomy for Management of Graves’ Disease in the United States , 2010, World Journal of Surgery.

[75]  L. Bartalena,et al.  Clinical practice. Graves' ophthalmopathy. , 2009, The New England journal of medicine.

[76]  E. Efremidou,et al.  The efficacy and safety of total thyroidectomy in the management of benign thyroid disease: a review of 932 cases. , 2009, Canadian journal of surgery. Journal canadien de chirurgie.

[77]  E. Pearce,et al.  Treatment options for Graves disease: a cost-effectiveness analysis. , 2008, Journal of the American College of Surgeons.

[78]  Y. Erbil,et al.  The effect of anti-thyroid drug treatment duration on thyroid gland microvessel density and intraoperative blood loss in patients with Graves' disease. , 2008, Surgery.

[79]  L. Delbridge,et al.  Surgery versus radioiodine therapy as definitive management for graves' disease: the role of patient preference. , 2007, Thyroid : official journal of the American Thyroid Association.

[80]  R. England,et al.  How we do it: Surgery should be considered equally with I131 and thionamide treatment as first‐line therapy for thyrotoxicosis , 2006, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[81]  B. Hamberger,et al.  Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. , 2005, Thyroid : official journal of the American Thyroid Association.

[82]  Q. Duh,et al.  Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease? , 2005, Thyroid : official journal of the American Thyroid Association.

[83]  E. Mittendorf,et al.  Thyroidectomy for selected patients with thyrotoxicosis. , 2001, Archives of otolaryngology--head & neck surgery.

[84]  M. Minuto,et al.  Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol's iodide solution in patients with diffuse toxic goiter. , 2000, Journal of the American College of Surgeons.

[85]  J. Walsh,et al.  Management of Graves' disease in Australia. , 2000, Australian and New Zealand journal of medicine.

[86]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.